Aethlon Medical Q3 FY2026: cash $7.0M; operating loss $2.06M up 13.6% YoY

AETHLON MEDICAL INC

2026-Q3 EPS reported -$11.01

Cash balance of ~$7.0M as of Dec 31, 2025; no revenue reported.
Q3 operating loss of $2.06M vs $1.81M in prior year, driven by higher payroll costs.
Nine-month operating expenses down 26.9% to $5.36M from $7.34M YoY.
Cohort 2 of Australian oncology trial progressing; Hemopurifier compatibility study with SLAMB system underway.
Preclinical Long COVID data published on bioRxiv; submitted for peer review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.